Evaluation of sFlt-1 and PlGF for predicting preeclampsia in pregnant women with diabetes mellitus

Abstract

AIM: The aim of this study was to evaluate soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) levels in the blood of women with various types of diabetes mellitus, depending on the correction method applied, and to determine the prognostic significance of the sFlt-1 / PlGF ratio for predicting the development of preeclampsia in this patient population.

MATERIALS AND METHODS: We examined 140 pregnant women who were included in six main study groups: type 1 diabetes mellitus (with or without pregravid preparation), type 2 diabetes mellitus (diet therapy or insulin therapy), and gestational diabetes mellitus (diet therapy or insulin therapy). The comparison groups consisted of pregnant women with preeclampsia and patients without complications of pregnancy. Using electrochemiluminescence analysis, PlGF and sFlt-1 levels in the blood serum were determined twice, at 11⁺⁰–13⁺⁶ and 30⁺⁰–33⁺⁶ weeks of gestation. Statistical data processing was performed using the IBM SPSS Statistics version 23 and GraphPad Prism version 8.0 software packages.

RESULTS: In the blood serum of pregnant women with diabetes mellitus in the first and third trimesters of pregnancy, we found an increase in sFlt-1 level and a decrease in PlGF level, as well as an increase in the sFlt-1 / PlGF ratio. These changes were most pronounced in individuals with type 1 diabetes mellitus without pregravid preparation and with type 2 diabetes mellitus on insulin therapy. In patients with pregestational types of diabetes mellitus, the sFlt-1 / PlGF ratio was a predictor of preeclampsia already in the early stages of pregnancy. Analysis of the ROC curve showed that the threshold sFlt-1 / PlGF ratio for predicting preeclampsia in pregnant women with diabetes mellitus in the first trimester was 32.5 (sensitivity 92.9%, specificity 50.0%) and in the third trimester 71.8 (sensitivity 85.7%, specificity 82.3%) with AUC 0.78 (95% CI 0.68–0.88) and 0.89 (95% CI 0.83–0.95), respectively. In the first trimester, the positive and negative predictive values of the sFlt-1 / PlGF ratio as a predictor of preeclampsia in pregnant women with diabetes mellitus were 63.3% and 97.6%, respectively; in the third trimester, 38.9% and 93.6%, respectively.

CONCLUSIONS: Blood level alterations of PlGF and sFlt-1 are characteristic of patients with diabetes mellitus in the first and third trimesters of pregnancy. An increase in the sFlt-1 / PlGF ratio is associated with a higher incidence of unfavorable perinatal outcomes in women with impaired carbohydrate metabolism. Determination of the sFlt-1 / PlGF ratio is a valid method for predicting the development or absence of preeclampsia in women with diabetes mellitus.

Keywords

preeclampsia / diabetes mellitus / placental growth factor / soluble fms-like tyrosine kinase-1 / PlGF / sFlt-1

References

[1] Poon LC, Shennan A, Hyett JA, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 2019;145(Suppl 1):1–33. DOI: 10.1002/ijgo.12802

[2] Poon L.C., Shennan A., Hyett J.A. et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention//Int. J. Gynaecol. Obstet. 2019. Vol. 145. Suppl. 1. P. 1–33. DOI: 10.1002/ijgo.12802

[3] Mol BWJ, Roberts CT, Thangaratinam S, et al. Pre-eclampsia. Lancet. 2016;387(10022):999–1011. DOI: 10.1016/S0140-6736(15)00070-7

[4] Mol B.W.J., Roberts C.T., Thangaratinam S. et al. Pre-eclampsia//Lancet. 2016. Vol. 387. No. 10022. P. 999–1011. DOI: 10.1016/S0140-6736(15)00070-7

[5] Ma’ayeh M, Rood KM, Kniss D, Costantine MM. Novel Interventions for the prevention of preeclampsia. Curr Hypertens Rep. 2020;22(2):17. DOI: 10.1007/s11906-020-1026-8

[6] Ma’ayeh M., Rood K.M., Kniss D., Costantine M.M. Novel interventions for the prevention of preeclampsia//Curr. Hypertens. Rep. 2020. Vol. 22. No. 2. P. 17. DOI: 10.1007/s11906-020-1026-8

[7] Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda). 2009;24:147–158. DOI: 10.1152/physiol.00043.2008

[8] Wang A., Rana S., Karumanchi S.A. Preeclampsia: the role of angiogenic factors in its pathogenesis//Physiology (Bethesda). 2009. Vol. 24. P. 147–158. DOI: 10.1152/physiol.00043.2008

[9] Chau K, Hennessy A, Makris A. Placental growth factor and pre-eclampsia. J Hum Hypertens. 2017;31(12):782–786. DOI: 10.1038/jhh.2017.61

[10] Chau K., Hennessy A., Makris A. Placental growth factor and pre-eclampsia//J. Hum. Hypertens. 2017. Vol. 31. No. 12. P. 782–786. DOI: 10.1038/jhh.2017.61

[11] Yusuf AM, Kahane A, Ray JG. First and second trimester serum sFlt-1/PlGF ratio and subsequent preeclampsia: A systematic review. J Obstet Gynaecol Can. 2018;40(5):618–626. DOI: 10.1016/j.jogc.2017.07.014

[12] Yusuf A.M., Kahane A., Ray J.G. First and second trimester serum sFlt-1/PlGF ratio and subsequent preeclampsia: A systematic review//J. Obstet. Gynaecol. Can. 2018. Vol. 40. No. 5. P. 618–626. DOI: 10.1016/j.jogc.2017.07.014

[13] Kholin AM, Ivanets TYu, Khodzhaeva ZS, Gus AI. Screening of early preeclampsia in the first trimester of pregnancy on the basis of combined estimate of maternal serum placental growth factor and uterine artery doppler. Obstetrics and Gynecology. 2015;(5):42–48. (In Russ.)

[14] Холин А.М., Иванец Т.Ю., Ходжаева З.С., Гус А.И. Скрининг ранней преэклампсии в I триместре беременности на основе комбинированной оценки материнского сывороточного плацентарного фактора роста и допплерометрии маточных артерий//Акушерство и гинекология. 2015. № 5. C. 42–48.

[15] Ivanets TYu, Kan NE, Tyutyunnik VL, et al. The role of the soluble fms-like tyrosin kinase-1 / the placental growth factor ratio in the diagnostics of preeclampsia in physiological pregnancy and pregnancy after IVF. Obstetrics and Gynecology. 2018;(3):37–43. (In Russ.). DOI: 10.18565/aig.2018.3.37-42

[16] Иванец Т.Ю., Кан Н.Е., Тютюнник В.Л. и др. Роль соотношения растворимой fms-подобной тирозинкиназы-1 и плацентарного фактора роста в диагностике преэклампсии при физиологической беременности и беременности после вспомогательных репродуктивных технологий//Акушерство и гинекология. 2018. № 3. C. 37–43. DOI: 10.18565/aig.2018.3.37-42

[17] International Diabetes Federation. IDF Diabetes Atlas. 9th edn. Brussels, Belgium; 2019.

[18] International Diabetes Federation. IDF Diabetes Atlas. 9th ed. Brussels, 2019.

[19] Weissgerber TL, Mudd LM. Preeclampsia and diabetes. Curr Diab Rep. 2015;15(3):9. DOI: 10.1007/s11892-015-0579-4

[20] Weissgerber T.L., Mudd L.M. Preeclampsia and diabetes//Curr. Diab. Rep. 2015. Vol. 15. No. 3. P. 9. DOI: 10.1007/s11892-015-0579-4

[21] Huynh J, Dawson D, Roberts D, Bentley-Lewis R. A systematic review of placental pathology in maternal diabetes mellitus. Placenta. 2015;36(2):101–114. DOI: 10.1016/j.placenta.2014.11.021

[22] Huynh J., Dawson D., Roberts D., Bentley-Lewis R. A systematic review of placental pathology in maternal diabetes mellitus//Placenta. 2015. Vol. 36. No. 2. P. 101–114. DOI: 10.1016/j.placenta.2014.11.021

[23] Mitsui T, Tani K, Maki J, et al. Upregulation of angiogenic factors via protein kinase C and hypoxia-induced factor-1 pathways under high-glucose conditions in the placenta. Acta Med Okayama. 2018;72(4):359–367. DOI: 10.18926/AMO/56171

[24] Mitsui T., Tani K., Maki J. et al. Upregulation of angiogenic factors via protein kinase C and hypoxia-induced factor-1 pathways under high-glucose conditions in the placenta//Acta Med. Okayama. 2018. Vol. 72. No. 4. P. 359–367. DOI: 10.18926/AMO/56171

[25] Ottanelli S, Napoli A, Clemenza S, et al. Hypertension and preeclampsia in pregnancy complicated by diabetes. In: Lapolla A, Metzger BE, editors. Gestational Diabetes. A Decade after the HAPO Study. Vol. 28. Basel: Karger; 2020:171–182. DOI: 10.1159/000480173

[26] Ottanelli S., Napoli A., Clemenza S. et al. Hypertension and preeclampsia in pregnancy complicated by diabetes//Gestational Diabetes. A Decade after the HAPO Study. Ed. by A. Lapolla, B.E. Metzger. Vol. 28. Basel: Karger, 2020. P. 171–182. DOI: 10.1159/000480173

[27] Powers RW, Jeyabalan A, Clifton RG, et al. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS One. 2010;5(10):e13263. DOI: 10.1371/journal.pone.0013263

[28] Powers R.W., Jeyabalan A., Clifton R.G. et al. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies//PLoS One. 2010;5(10):e13263. DOI: 10.1371/journal.pone.0013263

[29] El-Tarhouny SA, Almasry SM, Elfayomy AK, et al. Placental growth factor and soluble Fms-like tyrosine kinase 1 in diabetic pregnancy: A possible relation to distal villous immaturity. Histol Histopathol. 2014;29(2):259–272. DOI: 10.14670/HH-29.259

[30] El-Tarhouny S.A., Almasry S.M., Elfayomy A.K. et al. Placental growth factor and soluble Fms-like tyrosine kinase 1 in diabetic pregnancy: A possible relation to distal villous immaturity//Histol. Histopathol. 2014. Vol. 29. No. 2. P. 259–272. DOI: 10.14670/HH-29.259

[31] Cohen AL, Wenger JB, James-Todd T, et al. The association of circulating angiogenic factors and HbA1c with the risk of preeclampsia in women with preexisting diabetes. Hypertens Pregnancy. 2014;33(1):81–92. DOI: 10.3109/10641955.2013.837175

[32] Cohen A.L., Wenger J.B., James-Todd T. et al. The association of circulating angiogenic factors and HbA1c with the risk of preeclampsia in women with preexisting diabetes//Hypertens. Pregnancy. 2014. Vol. 33. No. 1. P. 81–92. DOI: 10.3109/10641955.2013.837175

[33] Vestgaard M, Sommer MC, Ringholm L, et al. Prediction of preeclampsia in type 1 diabetes in early pregnancy by clinical predictors: a systematic review. J Matern Fetal Neonatal Med. 2018;31(14):1933–1939. DOI: 10.1080/14767058.2017.1331429

[34] Vestgaard M., Sommer M.C., Ringholm L. et al. Prediction of preeclampsia in type 1 diabetes in early pregnancy by clinical predictors: a systematic review//J. Matern. Fetal. Neonatal. Med. 2018. Vol. 31. No. 14. P. 1933–1939. DOI: 10.1080/14767058.2017.1331429

[35] Bartsch E, Medcalf KE, Park AL, Ray JG, High risk of Pre-eclampsia Identification Group. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ. 2016;353:i1753. DOI: 10.1136/bmj.i1753

[36] Bartsch E., Medcalf K.E., Park A.L., Ray J.G. High risk of Pre-eclampsia Identification Group. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies//BMJ. 2016. Vol. 353. P. i1753. DOI: 10.1136/bmj.i1753

[37] Gestacionnyj saharnyj diabet: diagnostika, lechenie, poslerodovoe nabljudenie. Klinicheskie rekomendacii (protokol lechenija). Ministerstvo Zdravoohranenija Rossijskoj Federacii. Pis’mo ot 17 dekabrja 2013. No. 15-4/10/2-9478. (In Russ.). [cited 2021 July 1]. Available from: http://zdrav.spb.ru/media/komzdrav/documents/document/file/gestantsionni_sax_diabet_.pdf

[38] Гестационный сахарный диабет: диагностика, лечение, послеродовое наблюдение. Клинические рекомендации (протокол лечения). Министерство здравоохранения Российской Федерации. Письмо от 17 декабря 2013 г. № 15-4/10/2-9478. [дата обращения 1.07.2021]. Доступ по ссылке: http://zdrav.spb.ru/media/komzdrav/documents/document/file/gestantsionni_sax_diabet_.pdf

[39] Gipertenzivnye rasstrojstva vo vremja beremennosti, v rodah i poslerodovom periode. Prejeklampsija. Jeklampsija. Klinicheskie rekomendacii (protokol lechenija). Pis’mo Ministerstva zdravoohranenija RF ot 7 ijunja 2016. No. 15-4/10/2-3483. (In Russ.). [cited 2021 July 1]. Available from: https://rd1.medgis.ru/uploads/userfiles/shared/StandartMed/Protokol-acusher/2.pdf

[40] Гипертензивные расстройства во время беременности, в родах и послеродовом периоде. Преэклампсия. Эклампсия. Клинические рекомендации (Протокол лечения). Письмо Министерства здравоохранения РФ от 7 июня 2016 г. № 15-4/10/2-3483. [дата обращения 1.07.2021]. Доступ по ссылке: https://rd1.medgis.ru/uploads/userfiles/shared/StandartMed/Protokol-acusher/2.pdf

[41] Ong CY, Lao TT, Spencer K, Nicolaides KH. Maternal serum level of placental growth factor in diabetic pregnancies. J Reprod Med. 2004;49(6):477–480.

[42] Ong C.Y., Lao T.T., Spencer K., Nicolaides KH. Maternal serum level of placental growth factor in diabetic pregnancies//J. Reprod. Med. 2004. Vol. 49. No. 6. P. 477–480.

[43] Gorkem U, Togrul C, Arslan E. Relationship between elevated serum level of placental growth factor and status of gestational diabetes mellitus. J Matern Fetal Neonatal Med. 2020;33(24):4159–4163. DOI: 10.1080/14767058.2019.1598361

[44] Gorkem U., Togrul C., Arslan E. Relationship between elevated serum level of placental growth factor and status of gestational diabetes mellitus//J. Matern. Fetal. Neonatal. Med. 2020. Vol. 33. No. 24. P. 4159–4163. DOI: 10.1080/14767058.2019.1598361

[45] Cohen A, Lim KH, Lee Y, et al. Circulating levels of the antiangiogenic marker soluble FMS-like tyrosine kinase 1 are elevated in women with pregestational diabetes and preeclampsia: angiogenic markers in preeclampsia and preexisting diabetes. Diabetes Care. 2007;30(2):375–377. DOI: 10.2337/dc06-1514

[46] Cohen A., Lim K.H., Lee Y. et al. Circulating levels of the antiangiogenic marker soluble FMS-like tyrosine kinase 1 are elevated in women with pregestational diabetes and preeclampsia: angiogenic markers in preeclampsia and preexisting diabetes//Diabetes Care. 2007. Vol. 30. No. 2. P. 375–377. DOI: 10.2337/dc06-1514

[47] Yu Y, Jenkins AJ, Nankervis AJ, et al. Anti-angiogenic factors and pre-eclampsia in type 1 diabetic women. Diabetologia. 2009;52(1):160–168. DOI: 10.1007/s00125-008-1182-x

[48] Yu Y., Jenkins A.J., Nankervis A.J. et al. Anti-angiogenic factors and pre-eclampsia in type 1 diabetic women//Diabetologia. 2009. Vol. 52. No. 1. P. 160–168. DOI: 10.1007/s00125-008-1182-x

[49] Holmes VA, Young IS, Patterson CC, et al. The role of angiogenic and antiangiogenic factors in the second trimester in the prediction of preeclampsia in pregnant women with type 1 diabetes. Diabetes Care. 2013;36(11):3671–3677. DOI: 10.2337/dc13-0944

[50] Holmes V.A., Young I.S., Patterson C.C. et al. The role of angiogenic and antiangiogenic factors in the second trimester in the prediction of preeclampsia in pregnant women with type 1 diabetes//Diabetes Care. 2013. Vol. 36. No. 11. P. 3671–3677. DOI: 10.2337/dc13-0944

[51] Vieira MC, Begum S, Seed PT, et al. Gestational diabetes modifies the association between PlGF in early pregnancy and preeclampsia in women with obesity. Pregnancy Hypertens. 2018;13:267–272. DOI: 10.1016/j.preghy.2018.07.003

[52] Vieira M.C., Begum S., Seed P.T. et al. Gestational diabetes modifies the association between PlGF in early pregnancy and preeclampsia in women with obesity//Pregnancy Hypertens. 2018. Vol. 13. P. 267–272. DOI: 10.1016/j.preghy.2018.07.003

[53] Nuzzo AM, Giuffrida D, Moretti L, et al. Placental and maternal sFlt1/PlGF expression in gestational diabetes mellitus. Sci Rep. 2021;11(1):2312. DOI: 10.1038/s41598-021-81785-5

[54] Nuzzo A.M., Giuffrida D., Moretti L. et al. Placental and maternal sFlt1/PlGF expression in gestational diabetes mellitus//Sci. Rep. 2021. Vol. 11. No. 1. P. 2312. DOI: 10.1038/s41598-021-81785-5

[55] Zen M, Padmanabhan S, Zhang K, et al. Urinary and serum angiogenic markers in women with preexisting diabetes during pregnancy and their role in preeclampsia prediction. Diabetes Care. 2020;43(1):67–73. DOI: 10.2337/dc19-0967

[56] Zen M., Padmanabhan S., Zhang K. et al. Urinary and serum angiogenic markers in women with preexisting diabetes during pregnancy and their role in preeclampsia prediction//Diabetes Care. 2020. Vol. 43. No. 1. P. 67–73. DOI: 10.2337/dc19-0967

[57] Zeisler H, Llurba E, Chantraine F, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374(1):13–22. DOI: 10.1056/NEJMoa1414838

[58] Zeisler H., Llurba E., Chantraine F. et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia//N. Engl. J. Med. 2016. Vol. 374. No. 1. P. 13–22. DOI: 10.1056/NEJMoa1414838

[59] Herraiz I, Llurba E, Verlohren S, Galindo A; Spanish Group for the Study of Angiogenic Markers in Preeclampsia. Update on the diagnosis and prognosis of preeclampsia with the aid of the sFlt-1/PlGF ratio in singleton pregnancies. Fetal Diagn Ther. 2018;43(2):81–89. DOI: 10.1159/000477903

[60] Herraiz I., Llurba E., Verlohren S., Galindo A.; Spanish Group for the Study of Angiogenic Markers in Preeclampsia. Update on the diagnosis and prognosis of preeclampsia with the aid of the sFlt-1/PlGF ratio in singleton pregnancies//Fetal. Diagn. Ther. 2018. Vol. 43. No. 2. P. 81–89. DOI: 10.1159/000477903

[61] Verlohren S, Herraiz I, Lapaire O, et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension. 2014;63(2):346–352. DOI: 10.1161/HYPERTENSIONAHA.113.01787

[62] Verlohren S., Herraiz I., Lapaire O. et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia//Hypertension. 2014. Vol. 63. No. 2. P. 346–352. DOI: 10.1161/HYPERTENSIONAHA.113.01787

[63] Bettiher OA. Osobennosti patogeneza i klinicheskih projavlenij prejeklampsii u beremennyh s gestacionnym saharnym diabetom. [dissertation abstract]. St. Petersburg; 2020. [cited 2021 Jul 1]. Available from: https://www.dissercat.com/content/osobennosti-patogeneza-i-klinicheskikh-proyavlenii-preeklampsii-u-beremennykh-s-gestatsionny.

[64] Беттихер О.А. Особенности патогенеза и клинических проявлений преэклампсии у беременных с гестационным сахарным диабетом: автореф. дис. … кандидат медицинских наук. Санкт-Петербург, 2020. [дата обращения 1.07.2021]. Доступ по ссылке: https://www.dissercat.com/content/osobennosti-patogeneza-i-klinicheskikh-proyavlenii-preeklampsii-u-beremennykh-s-gestatsionny.

RIGHTS & PERMISSIONS

Eсо-Vector